Comparative Pharmacology
Head-to-head clinical analysis: BENZTHIAZIDE versus ENDURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZTHIAZIDE versus ENDURON.
BENZTHIAZIDE vs ENDURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium reabsorption and increasing excretion of water, sodium, chloride, potassium, and hydrogen ions. Also causes vasodilation via direct arteriolar relaxation.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing water excretion.
Adults: 25-50 mg orally once daily initially, may increase to 100 mg daily in a single dose or two divided doses. Maximum dose: 100 mg/day.
Oral, 2.5–5 mg once daily. Maximum dose 10 mg/day.
None Documented
None Documented
Clinical Note
moderateBenzthiazide + Mecamylamine
"The risk or severity of adverse effects can be increased when Benzthiazide is combined with Mecamylamine."
Clinical Note
moderateDexketoprofen + Benzthiazide
"The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Benzthiazide."
Terminal elimination half-life: 8-12 hours; clinical context: supports once-daily dosing for hypertension, but duration of action may extend beyond half-life due to tissue distribution.
Terminal elimination half-life: 24-48 hours (mean 36 hours); prolonged in renal impairment or heart failure, allowing once-daily dosing.
Renal: ~90% (60% unchanged, 30% as glucuronide conjugate); biliary/fecal: minimal (<5%).
Primarily renal (approximately 50-70% as unchanged drug); biliary/fecal (15-30%); dose adjustment required in renal impairment (CrCl <30 mL/min).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic